Patent No. 6,630,507 awarded in 2003 covered cannabinoids as antioxidants and neuroprotectants, highlighting federal research into potential therapeutic uses.
That patent sat uneasily beside marijuana’s Schedule I status, which defined the drug as having no currently accepted medical use even as government researchers studied cannabinoid applications.
The commentary argues the deeper scientific story is the endocannabinoid system — a biological network involved in appetite, mood, sleep, pain, memory and inflammation.
Research traced that system from THC’s identification in 1964 to the discovery of cannabinoid receptors and body-made compounds such as anandamide, shifting the debate from the cannabis plant to human biology.